Meeting
2022 ASCO Annual Meeting
Gemcitabine-docetaxel in patients with relapsed high-grade osteosarcoma after first-line treatment with high-dose ifosfamide: A retrospective multicenter study.
Authors
Maria Grazia Pionelli
Pediatric Onco-Hematology, A.O.U Città della Salute e della Scienza, University of Turin, Torino, Italy
Maria Grazia Pionelli , Sebastian Dorin Asaftei , Cristina Meazza , Alessandra Longhi , Angela Tamburini , Luca Coccoli , Alessandra Merlini , Celeste Cagnazzo , Tirtei Tirtei , Franca Fagioli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT04651179
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11520)
DOI
10.1200/JCO.2022.40.16_suppl.11520
Abstract #
11520
Poster Bd #
425
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).
First Author: Nam Bui
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2017 ASCO Annual Meeting
Apatinib for patients with unresectable high-grade osteosarcoma progressing after standard chemotherapy: A multi-center retrospective study.
First Author: Wenxi Yu
Poster
2015 ASCO Annual Meeting
Synergistic effects of cabozantinib to temozolomide and bevacizumab in patients with heavily pretreated relapsed uterine leiomyosarcoma.
First Author: Sayaka Ikeda